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ABSTRACT
Background and aims: Chromosomal instability (CIN) is
recognised as a hallmark of cancer and is caused by a
spindle assembly checkpoint disorder or chromosome
mis-segregation during mitosis. Although the recent
identification of human shugoshin (hSgo1), an important
player in proper chromosome segregation, has suggested
the involvement of hSgo1 in colorectal tumourigenesis,
little is known about how it is involved. The aim of this
study was to obtain information about the status of hSgo1
in human colorectal cancer.
Method and results: Among the 46 colorectal cancer
cases, hSgo1 mRNA expression was decreased in the
tumour tissue in comparison with the corresponding
normal tissue (p= 0.032). Human Sgo1-downregulated
tumours (tumour to normal mucosa ratio,0.5) had
preferential location on the left side large bowel rather
than on the right side (p= 0.012), and a higher variation
of centromere numbers revealed by fluorescence in situ
hybridisation (FISH). To assess the effects of hSgo1
downregulation, hSgo1 knockdown was performed by
transfecting the diploid HCT116 cell line with a short
hairpin RNA expression vector. hSgo1 knockdown cells
proliferated slowly because of both G2/M arrest and
apoptosis (p,0.001), and markers of CIN in the form of
aneuploidy (p,0.001) and micronuclei (p,0.005) were
later observed in hSgo1 knockdown cells. Increased
centrosome amplification (p,0.05), the presence of
binucleated cells and mitotic catastrophes were also
noted in hSgo1 knockdown cells.
Conclusions: These findings suggest that hSgo1-down-
regulated colorectal cancers have a clinicopathological
character of CIN, and hSgo1 downregulation leads to CIN
in colorectal cancer cells.
In colorectal cancer progression, two forms of
genomic instability have been identified: micro-
satellite instability (MIN) and chromosomal
instability (CIN).1 2 MIN is generally due to
inactivation of mismatch repair (MMR) genes such
as MSH2 and MLH1,3 and about 15% of sporadic
colorectal cancers show some form of MIN.4 On
the other hand, about 85% of colorectal cancers
display recurrent and tumour-specific chromosome
alterations.5 The identification of specific patterns
of chromosome gains and losses during tumour
progression is consistent with the idea that CIN is
an aetiological factor in colorectal cancer, but the
definitive molecular basis of CIN remains elusive.
Some of the culprits for chromosome alterations in
general may be mutations of spindle assembly
checkpoint genes. Moreover, previous data have
suggested that chromosome mis-segregation during
mitosis is the main cause of aneuploidy in cancer
cells, and that it contributes to oncogenesis.6
In 2004, shugoshin (Sgo) protein was identified
in budding and fission yeasts as a protector of
centromeric cohesion in meiosis.7 Sgo is conserved
among eukaryotic organisms including vertebrates.
One of the two human Sgo proteins (hSgo1 and
hSgo2), hSgo1 (also called shugoshin-like 1
(SGOL1)) has been shown to be essential to
accurate chromosome segregation during both
mitosis and meiosis.8 9 Coordinated chromosome
segregation also depends on the function of Polo-
like kinase and Aurora B kinase,10 11 which are
overexpressed in human tumours,12–14 and of
BUB1,15 which is downregulated in colorectal
cancer.16 These findings concerning hSgo1 and the
other chromosome segregation-regulating proteins
suggest that hSgo1 may also participate in the
pathogenesis of CIN in tumours, but the mechan-
ism has never been investigated in detail.
In this study, we searched for the clinicopatho-
logical significance of hSgo1 alterations in human
colorectal cancer cases and analysed the effects of
hSgo1 alterations in a human cell line.
MATERIALS AND METHODS
Tissue samples and cell lines
Tissue from cases of primary colorectal cancer was
surgically resected at the Hamamatsu University
School of Medicine, University Hospital. The
resected tissue was excised within 30 min after
the operation from tumour tissue and correspond-
ing non-tumour tissue .5 cm from the tumour.
The colorectal cell line used in this study was
HCT116.17 The cells were cultured in RPMI 1640
medium supplemented with 10% fetal bovine
serum (FBS) and penicillin–streptomycin (100 mg/
ml and 100 U/ml, respectively), and they were
maintained at 37uC in a 5% CO2/95% air incu-
bator. The study design was approved by the
Institutional Review Board (IRB) of Hamamatsu
University School of Medicine.
Microdissection
Frozen sections of the colorectal cancer tissue were
stained with H&E. Cancerous cell clusters in
stained sections were examined and microdissected
under an inverted microscope (Olympus IX71;
Olympus, Tokyo, Japan) equipped with a micro-
dissection device (MicroDissector; Eppendorf AG,
Hamburg, Germany). Areas of interest were
microdissected with an ultrasonically oscillating
needle, and the tissue particles obtained were
aspirated into a pipette tip with a piezo-driven
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micropipette (fig 1A). The microdissected materials were used
for DNA or RNA extraction.
DNA isolation, PCR followed by direct sequencing, PCR-single
strand conformation polymorphism (SSCP)
Genomic DNA was isolated by standard procedures.18 For
mutation and loss of heterozygosity (LOH) analysis, we
performed PCR-SSCP using 10 primer sets displayed in table 1,
and the PCR products that produced an abnormally shifted
band in the SSCP analysis were directly sequenced according to
the method described previously.19
RNA extraction and quantitative real-time reverse transcription
(qRT)-PCR
Total RNA was extracted from tumours and normal tissues by
using the commercially available ISOGEN kit (Nippongene,
Tokyo, Japan) according to the manufacturer’s instructions.
qRT-PCR was performed as previously described.20 cDNA was
synthesised from total RNA with a SuperScript II First-Strand
Synthesis System for RT-PCR (Invitrogen, Carlsbad, California,
USA). The cDNA was used as a template to perform qRT-PCR
of hSgo1 cDNA with a QuantiTect SYBR Green PCR kit
(QIAGEN, Hilden, Germany). The primers used were 5’-GAC
CCC AAT AGT GAT GAC AGC-3’ and 5’-GAA ATG ATT CTC
CTT GTC CTG G-3’ for the hSgo1 transcript, and 5’-AGG TGA
AGG TCG GAG TCA AC-3’ and 5’-CCA TGG GTG GAA TCA
TAT TG-3’ for the transcript of the control housekeeping gene,
the gene that encodes glyceraldehyde-3-phosphate dehydrogen-
ase (GAPDH). The relative amounts of the hSgo1 transcript in
the tumour tissue (T) and the normal tissue (N) were
standardised according to those of the GAPDH transcript. The
tumour to normal mucosa (T/N) ratio was calculated in each
case by using the standardised relative amounts of hSgo1
transcript in the tumour tissue and normal tissue.
Protein extraction and western blotting
Protein was extracted from H&E-stained frozen sections of
tumour tissue in which 90% of the tissue was occupied by
clusters of cancer cells. The frozen tissue and cultured cells were
solubilised in lysis buffer (10 mM N-2-hydroxyethylpiperazine-
N9-ethanesulfonic acid (HEPES)-KOH (pH 7.5), Nonidet P-40,
1 mM dithiothreitol (DTT), 0.5 mM EDTA, 1.5 mg/ml phe-
nylmethylsulfonyl fluoride (PMSF)) with an ultrasonic proces-
sor (Hielscher, Teltow, Germany) on ice and then centrifuged
(100 000 g) for 15 min at 4uC. The supernatant was mixed with
26SDS sample buffer (125 mmol/l Tris–HCl (pH 6.8), 4% SDS,
20% glycerol, 10% 2-mercaptoethanol, 0.2% bromophenol blue)
adjusted to 2.5 mg of protein/ml and heated for 10 min at 98uC.
The proteins mixed with 26SDS sumple buffer were separated
by electrophoresis on 12.5% SDS–polyacrylamide gels, and the
proteins in the gels were transferred to polyvinylidene fluoride
membranes (GE Healthcare Bio-Sciences, Fairfield, California,
USA) in a transfer apparatus (Atto, Tokyo, Japan). The
membranes were blocked with 1% skim milk and 0.1% Tween
in phosphate-buffered saline (PBS). Monoclonal anti-hSgo1
antibody (13G1) raised by Dr Suzuki of Jikei University21 and
diluted 1:500 in blocking buffer, antiphospho-histone H3
(Ser10) antibody (Millipore, Billerica, Massachusettts, USA)
diluted 1:500 in bocking buffer, and mouse anti-b-tubulin
antibody (GE Healthcare Bio-Sciences) diluted 1:1000 in
blocking buffer were used as the primary antibodies. Sheep
anti-mouse immunoglobulin G–horseradish peroxidase (HRP)-
linked F(ab9)2 fragment diluted 1:5000 in blocking buffer was
used as the secondary antibody. Antigens on the membrane
were detected with enhanced chemiluminescence detection
reagents (GE Healthcare Bio-Sciences).
Immunostaining of hSgo1 and Ki-67
Tissues were fixed in 10% formalin. The details of the
immunostaining procedure have been described elsewhere.22 In
brief, after incubation for 1 h with the anti-hSgo1 mouse
monoclonal antibody (13G1) diluted 1:50 or anti-Ki-67 mouse
monoclonal antibody (MIB1, DAKO, Copenhagen, Denmark)
diluted 1:50, polymer reagent (dextran backbone to which a
large number of peroxidase molecules and secondary antibody
molecules have been coupled) (ChemoMate ENVISION kit;
DAKO) was added. Colorisation development was performed
with 0.2 mg/ml 3-3’-diaminobenzidine tetrahydrochloride
(DAB) (DAKO) and 0.3% H2O2. Haematoxylin was used for
nuclear counterstaining.
Fluorescence in situ hybridisation (FISH)
For FISH analysis, the microwave-assisted FISH protocol was
performed as described previously.23 The centromere enumera-
tion probes (CEPs) were used to identify the numbers of
chromosomes 3, 12, 17 and 18 (CEP3, 12, 17 and 18; Vysis,
Abbott Park, Illinois, USA, respectively). The number of signals
per cell was counted in .200 cell nuclei. The modal signal
number was defined as the number of the chromosomes most
prevalent in tumour cells, and an abnormal signal number was
defined as any number of signals other than the modal number.
Construction of the short hairpin RNA (shRNA) expression
vector, and transfection
The hSgo1 shRNA expression vector was constructed by
inserting shRNA sequences targeting hSgo1 (target sequence:
5’-GTG AAA GAA GCC CAA GAT A-3’) into pSilencer 2.1-U6
puro (Applied Biosystems, Foster City, California, USA). The
negative control pSilencer 2.1-U6 puro vector expresses a
shRNA whose sequence is not found in the human genome
databases (target sequence: 5’-GTC AGG CTA TCG CGT ATC
G-3’). HCT116 cells cultured in 100 mm diameter dishes were
transiently transfected with 10 mg of shRNA expression vector
by means of Lipofectamine 2000 (Invitrogen). Transfected cells
were selected by culturing in 0.75 mg/ml puromycin-containing
culture medium for 48 h before use.
Table 1 Primers used for PCR amplification of hSgo1 exons
Exon Forward primer (5’–3’)* Reverse primer (5’–3’)
Size
(bp)
2 (2212)agtgcctgaggaggaagagag (+299)ttgggcttctttcactttgg 530
3 (+123)tgcaccatgccaaataatcag (+552)gcaatagctatgctggagcac 450
4 (+5575)gcatggcaccatgatagactg (+5828)gttgacatgatgcacatttcc 275
5 (+7205)gcataagtgtcctttggtttcc (+7461)tctcaaagaccttattttgccc 278
6 (+8776)gccatcagttgatcactgacaag (+9274)gtaaacgttcctggctgaatc 520
6 (+9221)caacacaatgcttgtcaatgg (+9614)tcggaatcatctcctgaacc 413
6 (+9540)tccgacaaaaagtgagcaatg (+9859)cctccaccagagaaacagatg 340
7 (+12 650)caacacagtgagagcccatc (+12 905)ctgctgggcttgctttattc 275
7 (+12 832)gcctgaaggatatcaccaatg (+13 020)tattccccccgacatgtatc 208
8 (+13 168)ttgggatgcttacattatgcc (+13 423)tatggcaatggctcactctg 256
*Nucleotide +1 is the A of the ATG translation initiation codon. The positions of the 5’
end of primers are indicated by the number upstream (2y) or downstream (+y) from
the A of the ATG translation initiation codon.
Colonic cancer
250 Gut 2009;58:249–260. doi:10.1136/gut.2008.149468
group.bmj.com on January 6, 2011 - Published by gut.bmj.comDownloaded from 
Table 2 Summary of the human shugoshin genetic polymorphisms in 30 colorectal cancer cases
Nucleotide change* Predicted effect
Number of cases with the variant-
type allele (%)
dbSNP ID{
Heterozygous
case Homozygous case
c.339+29T.C (IVS3+29T.C) Unknown 2 (6.7%) 2 (6.7%) rs170006703
c.416+39_42delGAAA (IVS4+39_42delGAAA) Unknown 11 (36.6%) 1 (3.3%) None
c.504A.T p.Thr168Thr 11 (36.6%) 4 (13.3%) None
c.1461C.T p.Pro487Pro 2 (6.7%) 4 (13.3%) None
c.1564+80G.C (IVS8+80G.C) Unknown 2 (6.7%) 1 (3.3%) None
*Nucleotide +1 is the A of the ATG translation initiation codon.
{dbSNP, http://www.ncbi.nlm.nih.gov/SNP/index.html.
Figure 1 Loss of heterozygosity (LOH)
analysis at the hSgo1 gene locus on 3p24
in colorectal cancer samples. (A)
Microdissection of colon cancer tissue in
H&E-stained sections. The histological
appearance of colon cancer is shown. The
middle panel is a higher magnification of
the boxed area in the top panel. The
bottom panel shows the section after that
in the middle panel and microdissection
under an inverted microscope (Olympus
IX71) equipped with a microdissection
device (MicroDissector). Scale bars:
100 mm. (B–D) Detection of LOH with
polymorphic markers (B,
c.416+39_42delGAAA; C, c.504A.T; D,
c.1461C.T) by PCR-SSCP (single strand
conformational polymorphism) and direct
sequencing. Tumour, tumour tissue;
normal, adjacent normal tissue. (E)
Summary of informative colorectal cancer
samples with LOH at the hSgo1 gene
locus on 3p24. Filled circles, informative
and retention of heterozygosity; open
circles, informative and LOH; NI, non-
informative.
Colonic cancer
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Cell proliferation assay
A cell counting Kit-8 (DOJINDO, Kumamoto, Japan) was used to
assess cell viability.24 A colony formation assaywas used to analyse
long-term cell proliferation. HCT116 cells (16105) transfected
with the negative control shRNA expression vector (Control
shRNA) or hSgo1 shRNA expression vector (hSgo1 shRNA) were
seeded in 0.75 mg/ml puromycin-containing culture medium and
incubated for 14 days. The colonies obtained were stained with
Giemsa solution (Merck, Darmstadt, Germany) and counted.
Fluorescence-activated cell sorting (FACS)
FACS analysis was performed for HCT116 cells transfected
with the negative control shRNA expression vector (Control
shRNA) or hSgo1 shRNA expression vector (hSgo1 shRNA)
as described previously.25 26 In brief, the cells were washed in
PBS, incubated in PBS for 10 min, and then trypsinised and
fixed in 80% ethanol. The fixed cells were incubated for
30 min with normal goat serum diluted at 1:30 in PBS, and
then for 2 h at room temperature in the presence of mouse
monoclonal antibody to human cyclin B1 (BD Pharmingen,
San Diego, California, USA) that had been diluted to 1:30 in
PBS. The cells were washed and incubated for an hour with
fluorescein isothiocyanate (FITC)-conjugated goat anti-mouse
IgG antibody diluted at 1:30 in PBS at room temperature.
The cells were washed again, resusupended in 50 mg/ml
propidium iodide and analysed by using a Beckman Coulter
Table 3 Profile of cases in which human shugoshin (hSgo1) expression was analysed by quantitative real-
time reverse transcription-PCR and comparison of clinicopathological parameters between the group in which
the tumour to normal mucosa (T/N) ratio of hSgo1 mRNA expression was>0.5 and the group in which it was
,0.5
Characteristic
hSgo1 T/N>0.5 hSgo1 T/N,0.5
p Value*(n=24) (n= 22)
Sex, no. (%) Male 13 (54.2) 16 (72.7)
Female 11 (45.8) 6 (27.3) 0.318
Age, no. (%) ,50 years 1 (4.2) 1 (4.5)
51–60 years 5 (20.8) 5 (22.7)
61–70 years 6 (25.0) 7 (31.8)
71–80 years 6 (25.0) 8 (36.4)
.81 years 6 (25.0) 1 (4.5) 0.624
Location, no. (%) Caecum 2 (8.3) 1 (4.5)
Ascending colon 8 (33.3) 2 (9.1)
Transverse colon 2 (8.3) 0 (0.0)
Descending coon 1 (4.2) 1 (4.5)
Sigmoid colon 5 (20.8) 5 (22.7)
Rectum 6 (25.0) 13 (59.1) 0.710
Left side of the large bowel 12 (50.0) 19 (86.4)
Right side of the large bowel 12 (50.0) 3 (13.6) 0.012
Rectum 6 (25.0) 13 (59.1)
Not rectum 18 (75.0) 9 (40.9) 0.040
Pathological classification, no. (%) Well differentiated 15 (62.5) 16 (72.7)
Not well differentiated 9 (37.5) 6 (27.3) 0.671
Lymphatic metastasis, no. (%) Positive 19 (79.2) 15 (68.2)
Negative 5 (20.8) 7 (31.8) 0.609
Depth, no. (%) A1 0 (0.0) 1 (4.5)
A2 1 (4.2) 2 (9.1)
Sm 1 (4.2) 2 (9.1)
Mp 1 (4.2) 3 (13.6)
Ss 9 (37.5) 7 (31.8)
Se 10 (41.6) 7 (31.8)
Si 2 (8.3) 0 (0.0) 0.999
Borrmann classification, no. (%) 0–1 1 (4.2) 1 (4.5)
2 21 (87.5) 19 (86.4)
3–4 2 (8.3) 2 (9.1) 0.739
Dukes classification, no. (%) A 2 (8.3) 4 (18.2)
B 3 (12.5) 3 (13.6)
C 19 (79.2) 15 (68.2) 0.808
*p Values were calculated by the x2 test.
Depths were defined based on the 6th Japanese Classification of Colorectal Carcinoma.
Colonic cancer
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Epics XL (Beckman Coulter, Fullerton, California, USA).
Single cell suspensions were prepared from paraffin-embedded
material as described previously.27
Time-lapse imaging
Cells maintained in culture medium in a 35 mm dish were
placed in an incubation chamber equipped with a time-
lapse imaging system (BioStation IM; Nikon, Tokyo,
Japan). Phase contrast images were captured at 10 min
intervals and then digitised with BioStation IM viewer
software.
Indirect immunofluorescence analysis
Indirect immunofluorescence analysis was performed as
described elsewhere.28 Cells were probed with anti-c-tubulin
monoclonal antibody (GTU88; Sigma-Aldrich, St Louis,
Missouri, USA) or anti-claudin-4 polyclonal antibody (Santa
Cruz Biotechnology, Santa Cruz, California, USA). Indirect
immunofluorescence labelling of c-tubulin or claudin-4 was
performed with Alexa Fluor 594-conjugated goat anti-mouse
secondary antibody (Molecular Probes, Eugene, Oregon, USA)
or FITC-conjugated mouse anti-goat secondary antibody
(Jackson ImmunoResearch Laboratories, West Grove,
Figure 2 Human shugoshin (hSgo1)
expression at the transcription and
protein level in colorectal cancer. (A)
Comparison of hSgo1 mRNA levels
between tumour tissue and adjacent
normal tissue among 46 cases by real-
time quantitative reverse transcription-
PCR. Relative hSgo1 mRNA expression
(tumour/normal (T/N)) in each case is
indicated by a column, and the cases are
numbered in order of decreasing relative
hSgo1 mRNA expression. Columns under
the solid line and under the broken line
have hSgo1 T/N,1.0 and hSgo1 T/
N,0.5, respectively. Differences
between the standardised hSgo1 mRNA
level in tumour tissue and adjacent
normal tissue were statistically analysed
by the Wilcoxon matched pairs test, and
the p value was 0.032. (B) Western
blotting of hSgo1. (C) Immunostaining of
tumour tissue and adjacent normal tissue
with anti-hSgo1 antibody and anti-Ki-67
antibody. Scale bars: 100 mm. Panels b,
d, f, h, j and l are high-power
magnifications of panels a, c, e, g, i and k,
respectively.
Colonic cancer
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Figure 3 Comparison between tumour location, mean centromeric number and centromeric number distribution in the group with a tumour to normal
mucosa ratio of human shugoshin (hSgo1) mRNA expression of 0.5 or more (hSgo1 T/N>0.5) and the group in which it was less than 0.5 (hSgo1 T/
N,0.5). (A) Comparison between tumour location in the two groups. Open circles, hSgo1 T/N>0.5 cases; filled circles, hSgo1 T/N,0.5 cases. The
percentages of left and right side colorectal cancer cases and of rectal and non-rectal cancer cases were statistically compared in the two groups. p
Values were calculated by the x2 test. (B)Mean signal number and signal number variations represent different characteristics of tumour cells. The cells
in the left and right upper panels have the same mean signal numbers (both have a mean number of two), but they have different signal variation. The
cells in the right lower panel have greater signal variation than those in the left lower panel. Original magnifications:6600. (C and D) Comparison
between the mean signal number per cell (C) and the SD of the signal number per case (D) in the two groups. Filled circles, mean (C) or SD (D) value in
each case. Open circles, average mean (C) or SD (D) value in each group. Centromeric probes for chromosomes 3, 12, 17 and 18 were used. The
number of signals per cell was counted in.200 cell nuclei. p Values were calculated by Student t test. (E) Frequency distribution histograms of cellular
DNA content. The arrowhead points to the population with near diploid aneuploidy in the cases of hSgo1 T/N=0.28.
Colonic cancer
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Pennsylvania, USA), and the nuclei were stained with 4’,6-
diamidino-2-phenylindole (DAPI) (Vector Laboratories,
Burlingame, California, USA).
RESULTS
Expression of hSgo1 mRNA and protein was downregulated in
the colorectal cancer cases
Among the 30 colorectal cancer cases tested, five hSgo1 genetic
polymorphisms were detected (table 2) and 31.2% of informa-
tive cases had LOH at the hSgo1 locus on 3p24, but there was no
mutation in the other allele (fig 1). To analyse expression of
hSgo1, qRT-PCR was used in 46 colorectal cancer cases (table 3).
In 22 of the 46 cases (47.8%) hSgo1 was significantly
downregulated (T/N ratio ,0.5) in the colorectal cancer tissue
in comparison with the expression level in the paired normal
mucosa (fig 2A). A statistical analysis revealed that hSgo1 was
significantly downregulated in colorectal cancers compared
with the corresponding normal tissues (p=0.032 in Wilcoxon
matched pairs test). Western blotting was then performed in 15
colorectal cancer cases with 13G1 monoclonal antibody to
hSgo1, which recognised both full-length hSgo1 protein and
proteolytic cleavage fragments.21 The results showed that
expression of the full-length protein product of hSgo1
(72 kDa) was decreased in 40% (6/15) (fig 2B). We also
performed immunohistochemical staining of tissue from the
colorectal cancer cases with the antibody used for western
blotting. In the non-tumour colonic mucosa, hSgo1 expression
was localised in the nuclei of the cells at the bottom and the
middle of the crypts, where the Ki-67-positive cells were located,
implying that the hSgo1-positive area overlapped with the
active proliferative zone of the crypt. In addition, hSgo1
expression decreased gradually toward the top of the normal
colonic crypts (fig 2C). In contrast, no gradient of hSgo1
expression was observed in the case with a T/N ratio of hSgo1
mRNA expression of 0.97, and diffuse hSgo1 expression was
Figure 4 Growth properties of human
shugoshin (hSgo1) knockdown cells. (A)
Western blot showing the efficiency of
hSgo1 knockdown by transfection of
HCT116 cells with hSgo1 short hairpin
RNA (shRNA) in comparison with
negative control shRNA. hSgo1
knockdown cells expressed a higher level
of phospho-histone H3 than the control
cells, suggesting accumulation of hSgo1
knockdown cells in mitosis. (B) WST-8
assay. Cells (5000 cells/well) of each
population were seeded in 100 ml of
culture medium in the wells of three 96-
well plastic plates, and one plate each
was incubated in a 5% CO2/95% air
incubator for 24, 48 and 72 h. After
incubation, 10 ml of WST-8 reagent
solution was added to each well, and the
plate was incubated for an additional 4 h
in the 5% CO2/95% air incubator. Cell
viability was measured by scanning with
a microplate reader at 450 nm. This
experiment was performed three times.
(C) Colony formation assay of puromycin-
resistant colonies of cells transfected
with the control shRNA expression vector
or the hSgo1 shRNA expression vector.
Colonies were counted 14 days post-
transfection. This experiment was
performed three times. (D) Fluorescence-
activated cell sorting (FACS) analysis of
the DNA content profile of
asynchronously growing cells 5 days
after transfection with the control shRNA
expression vector or hSgo1 shRNA
expression vector. Numbers show the
mean (SD) of three independent
experiments. (E) FACS analysis of DNA
and cyclin B1, which is highly expressed
in the G2/M phase. Cyclin B1 was highly
expressed in the 4N DNA population both
of control cells and of hSgo1 knockdown
cells. The black line represents the upper
boundary of cyclin B1 fluorescence as a
control. Blue dot plot, a cell with a 2N
DNA content; red dot plot: a cell with a
4N DNA content.
Colonic cancer
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observed in the tumour cells (fig 2C, panels e,f). The results for
the level of hSgo1 expression detected by immunohistochemical
staining reflected the level of hSgo1 mRNA expression (fig 2C,
panels i,j).
Clinicopathological characteristics of cases of colorectal
cancers in which hSgo1 was downregulated
To characterise further the cases of colorectal cancer in which
hSgo1 was downregulated, we compared the clinicopathological
parameters of those of the 46 colorectal cancer cases in which
the T/N ratio of hSgo1 mRNA expression was ,0.5 (hSgo1 T/
N,0.5) and in which it was 0.5 or more (hSgo1T/N>0.5)
(table 3). The tumours in the hSgo1 T/N,0.5 group tended to
be located on the left side of the large bowel (descending colon,
sigmoid colon and rectum p=0.012), especially in the rectum
(p=0.040), rather than in the other regions of the large bowel
(fig 3A).
To assess aneuploidy in the 46 cases we performed a FISH
analysis with a centromeric probe specific for chromosomes 3,
12, 17 and 18 (CEP3, 12, 17 and 18). Aneuploidy was assessed on
the basis of the mean signal number and the signal number
distribution which was calculated as the ‘‘SD of the signal
number’’ in each case (fig 3B). The difference between mean
signal number in the hSgo1 T/N,0.5 group and hSgo1T/N>0.5
group was not significant (fig 3C), but the signal number
distribution in the hSgo1 T/N,0.5 group appeared to be wider,
because there were higher SD values in the hSgo1 T/N,0.5
group, especially for chromosomes 3 and 18 (chromosome 3,
p=0.045; chromosome 18, 0.042; fig 3D). FACS analysis of the
cellular DNA content of paraffin-embedded colorectal cancer
cells showed aneuploidy when hSgo1 T/N was,0.5, as opposed
to diploidy when the hSgo1 T/N was >0.5 (fig 3E). These
results suggested a more unstable chromosome numerical
abnormality, which is a clinicopathological character of CIN,
in colorectal cancers in which hSgo1 is downregulated.
Figure 5 Observation of chromosomal
instability under human shugoshin
(hSgo1)-depleted conditions. (A)
Fluorescent in situ hybridisation (FISH)
analysis with centromeric probes for
chromosomes 12 (red) and 17 (green).
The nuclei were stained with 49,6-
diamidino-2-phenylindole (DAPI) (blue).
The numbers of chromosome 12
centromere signals and chromosome 17
centromere signals in cells with any
abnormal signals in these chromosomes
are shown as a fraction, with the former
number in red and the latter number in
green. hSgo1 knockdown cells (right
panels) showed aneuploidy or polyploidy,
in contrast to the parental cells (left upper
panel) and control short hairpin RNA
(shRNA) phenotype (left lower panel). (B)
Detection of micronuclei (white and
yellow arrowheads). The nuclei were
stained with DAPI (blue). The FISH
analysis (right lower panel) detected a
centromeric probe (red/chromosome 12)
in a micronucleus (yellow arrowhead).
Original magnifications:6600.
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Knockdown of hSgo1 in HCT116 leads to accumulation of mitotic
or aneuploid cells
Based on the results of the hSgo1 expression analysis in a
clinicopathological context, we next tested the in vitro effect of
hSgo1 depletion by transfecting a hSgo1 shRNA expression
vector that contains a puromycin resistance gene (hSgo1
shRNA) into the HCT116 cell line, which is well known for
its microsatellite instability due to a MMR defect. The hSgo1
shRNA expression vector reduced the hSgo1 protein expression
level in HCT116 cells to 14%, and hSgo1 knockdown cells
expressed a higher level of phospho-histone H3 than the control
cells (fig 4A). A WST-8 assay and a colony formation assay
showed that the hSgo1 shRNA-transfected cells proliferated
more slowly than the control HCT116 cells (fig 4B,C). To
scrutinise the mechanism whereby the hSgo1 knockdown cells
stopped their proliferation, we performed FACS analysis of cells
that had asynchronously grown for 5 days after puromycin
selection. The percentage of the sub-G1 population (apoptotic
cell population) in the hSgo1 knockdown cells was higher than
in the control cells (9.1% (0.29%) vs 4.4% (0.9%), p=0.002;
fig 4D), and the hSgo1 knockdown phenotype tended to have
more cells in the G2/M phase (4N DNA content) (27.4% (3.7%)
vs 11.6% (2.8%), p=0.009; fig 4D) and more cells with .4N
DNA content (9.4% (1.9%) vs (2.4% (0.7%), p=0.008; fig 4D)
than the control cells. The expression of cyclin B1 in the
population of hSgo1 knockdown cells with a 4N DNA content
was as high as in the control cell population with a 4N DNA
content (fig 4E), suggesting that hSgo1 knockdown affected
mitosis. These results indicate that knockdown of hSgo1 leads
not only to apoptotic cell death but to G2/M arrest or
aneuploidy/polyploidy.
Knockdown of hSgo1 leads to chromosomal instability
A FISH analysis was performed to assess the development of
aneuploidy/polyploidy in hSgo1 shRNA cells. We used CEP12
and 17 to count the chromosome number. A higher percentage
of cells with an abnormal signal number was observed among
the hSgo1 shRNA cells than the control shRNA cells or parental
cells (fig 5A). Cells with abnormal signal numbers, especially
four signals, were more frequent in the hSgo1 shRNA cells than
in the control shRNA cells or the parental cells (table 4A,
p,0.0001). The cytological features such as nucleoplasmic
bridges, micronuclei and nuclear blebs are well known
signatures of CIN.29 hSgo1 shRNA induced micronuclei in the
HCT116 cells (3.9% of parental cells, 2.4% of control shRNA
cells and 9.8% of hSgo1 shRNA cells, p,0.005) (table 4B, fig 5B).
This finding also indicates that hSgo1 shRNA led to CIN.
Time-lapse imaging of HCT116 cells transfected with hSgo1
shRNA
We thought that observation for a longer time than in any
previous studies would enable a more thorough description of
the effect of hSgo1 shRNA, thus time-lapse microscopy was
used to monitor cells through mitosis. Figure 6A(a) shows that
control shRNA cells initiated mitosis and underwent normal
cytokinesis. On the other hand, the hSgo1 shRNA cells initially
remained in a prolonged period of mitotic arrest (a period in
which the cells assumed a spherical shape), after which some
hSgo1 shRNA cells underwent an aberrant cell division into
three daughter cells (fig 6A(b)), some were binucleated cells,
probably due to cytokinesis defects30 (fig 6A(c)), and others
exited the mitotic phase without undergoing cell division
(which may correspond to ‘‘mitotic slippage’’ or ‘‘adaptation’’
of the cells31) (fig 6A(d)). Most cells shrank immediately after
mitosis and died within a day (mitotic apoptosis or catastrophe)
(fig 6A(e)). The indirect immunofluorescence analysis per-
formed using antibodies to c-tubulin, a core component of the
centrosome, revealed a higher percentage of hSgo1 shRNA cells
containing more than three centrosomes than among the
control cells (fig 6B, C). The indirect immunofluorescence
analysis showed that 5% of the hSgo1 shRNA cells were
binucleate, but that none of the control shRNA or parental cells
were (fig 6D). These results suggest that hSgo1 knockdown of
colorectal cancer cells is accompanied by the emergence of
Table 4 Distribution of numerical chromosome variability (A) and frequency of micronuclei (B) in human shugoshin (hSgo1) knockdown cells
A. Distribution of numerical chromosome variability*
Signal number 2 0 1 3 4 5 Total Other than 2{ p Value{
CEP12
Parental cell 212 (97.6)1 1 (0.5) 1 (0.5) 1 (0.5) 2 (0.9) 0 (0) 217 (100) 5 (2.4) reference
Control shRNA 227 (98.3) 0 (0) 1 (0.4) 1 (0.4) 2 (0.9) 0 (0) 231 (100) 4 (1.7) 0.743
hSgo1 shRNA 183 (82.4) 0 (0) 6 (2.7) 5 (2.3) 26 (11.7) 2 (0.9) 222 (100) 39 (17.6) ,0.0001
CEP17
Parental cell 208 (98.5) 0 (0) 1 (0.5) 0 (0) 2 (1.0) 0 (0) 211 (100) 3 (1.5) reference
Control shRNA 207 (98.6) 0 (0) 3 (1.4) 0 (0) 0 (0) 0 (0) 210 (100) 3 (2.4) 1
hSgo1 shRNA 193 (89.8) 1 (0.5) 5 (2.3) 5 (2.3) 11 (5.1) 0 (0) 215 (100) 22 (10.2) ,0.0001
B. Frequency of micronuclei
No micronuclei Micronuclei Total p Value"
Parental cell 196 (96.1) 8 (3.9) 204 (100) reference
Control shRNA 203 (97.6) 5 (2.4) 208 (100) 0.549
hSgo1 shRNA 193 (90.2) 21 (9.8) 214 (100) ,0.005
*Interphase fluorescence in situ hybridisation (FISH) was performed with a centromere enumeration probe (CEP) for chromosomes 12 and 17.
{Cell counts ‘‘other than 2’’ are the total numbers of cells containing 0, 1, 3, 4 or 5 signals.
{The percentages of cells with numerical chromosome abnormalities (any chromosome number other than 2) among the control short hairpin RNA (shRNA) phenotype and the
hSgo1 shRNA phenotype were statistically different compared with the percentage of cells with numerical chromosome abnormalities among the parental shRNA phenotype. p
Values were calculated by Fisher’s exact test.
1Numbers in parentheses are percentages of cells.
"The percentages of cells with micronuclei among the control shRNA phenotype and the hSgo1 shRNA phenotype were statistically different compared with the percentage of cells
with micronuclei among the parental cells. p Values were calculated by the x2 test.
Colonic cancer
Gut 2009;58:249–260. doi:10.1136/gut.2008.149468 257
group.bmj.com on January 6, 2011 - Published by gut.bmj.comDownloaded from 
Figure 6 Centrosome amplification, binucleated cells and mitotic slippage accompanied human shugoshin (hSgo1) knockdown in HCT116 cells. (A)
Time-lapse microscopy of the control short hairpin RNA (shRNA) phenotype (a) and the hSgo1 shRNA phenotype (b–e) 5 days post-transfection.
Images were captured at regular intervals over the course of the experiment, and selected images are shown. (b) Aberrant cell division into three
daughter cells. (c) A binucleated cell. Yellow arrowheads point to the nuclei in a binucleated cell. (d) After a prolonged period of mitotic arrest (up to
310 min, the cell continues to have a spherical shape), the cell (yellow arrows) exits the mitotic phase without undergoing cell division. (e) Mitotic
catastrophe. The cells enter the mitotic phase and become apoptotic. Original magnification,610. (B) Detection of centrosome amplification in the
hSgo1 shRNA phenotype. Cells were stained with anti-c-tubulin monoclonal antibody (red) and counterstained with 49,6-diamidino-2-phenylindole
(DAPI) (blue). (C) Percentages of cells containing more than three centrosomes in interphase and the mitotic phase. p Values were calculated by
Student t test. Columns represent the means of three independent experiments; bars, SD. (D) Detection of binucleated cell in the hSgo1 shRNA
phenotype. Cells were stained with anti-claudin-4 monoclonal antibody (green) and counterstained with DAPI (blue). Original magnification:6600.
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aberrant cell division, centrosome amplification and mitotic
slippage, as well as mitotic catastrophes.
DISCUSSION
We have investigated the clinicopathological significance of
hSgo1 in human colorectal cancer. The results showed (1) that
hSgo1 was downregulated at the transcriptional and protein
level in human colorectal cancers; (2) that the tumours of hSgo1
downregulation preferentially located on the left side large
bowel and tended to have a wider centromecic numerical
distribution in each tumour; and (3) that knockdown of hSgo1
in colorectal cancer cell lines leads to CIN. This is the first study
on the role of hSgo1 in gastrointestinal cancer.
Genetic alterations of hSgo1 in human carcinogenesis have
never been extensively elucidated. In terms of expression at the
transcriptional level, hSgo1 has been reported to be a breast
cancer-specific message,32 but no follow-up characterisations
have been performed. We found a lower level of hSgo1
expression at the transcription and protein level in colorectal
cancer tissue than in normal colorectal mucosa, suggesting a key
role for hSgo1 in colorectal carcinogenesis. In the same way as in
a previous study of another gene in which Kloth et al concluded
that there was no association between the tumour necrosis
factor a (TNFa) mRNA expression level and LOH at the TNFa
locus,33 no association between LOH at the hSgo1 locus and
hSgo1 mRNA expression level was found in our study,
suggesting that hSgo1 mRNA expression is controlled by
another factor, such as transcriptional or post-transcriptional
activity, and not by LOH. Suzuki et al reported that a western
blot analysis of human cell lines yielded proteolytic cleavage
fragments as well as full-length hSgo1 protein.21 In interphase
Xenopus egg extracts, Xenopus Sgo has been found to be
ubiquitinated and degraded by the anaphase-promoting com-
plex in vitro.8 hSgo1 may be degraded in the same manner,
although the precise mechanism is unknown.
Various biological differences between adenocarcinomas on the
right side and left side of the large bowel have been reported34—for
example that sporadic CIN tumours tend to be located on the left
side.35 36 The results of our study showing predominant left side
location of hSgo1-downregulated tumours is consistent with
these reports, and thus hSgo1 downregulation may be related to
CIN. Although our FISH analysis of 46 colorectal cancer cases did
not show any significant difference between mean signal number
in the hSgo1 T/N,0.5 group and the hSgo1 T/N>0.5 group, the
standard deviation of the signal number in each case was higher in
the hSgo1 T/N,0.5 group than in the hSgo1 T/N>0.5 group, a
finding that may reflect unstable chromosome number status
(near diploid aneuploidy) in hSgo1 T/N,0.5 tumours. To assess
CIN rigorously, our counts included CEP3 and 18, which were
found to be relatively stable, especially in early stage gastric
cancer, in the previous study.23 The results of the precise
assessment of chromosome numerical status supported the
clinical view of the CIN character of hSgo1-downregulated
colorectal cancers.
Recently, it was reported that hSgo1 knockdown causes
premature chromatid separation in vivo9 but that overexpres-
sion of hSgo1 did not alter the DNA content according to a
FACS analysis.21 In view of these hSgo1 knockdown effects, it is
conceivable that hSgo1 knockdown leads to CIN. However, it
should be noted that all the previous studies observed and
analysed the effects of hSgo1 alteration only over a relatively
short period (within the period of ‘‘one’’ cell cycle or mitotic
phase). Thus, the long-term observation of the hSgo1 knock-
down cells for several days to a week was essential to obtain
further insights into the role of hSgo1 in tumour cells. By
extending our observation period to a week, we were able track
the sequence of a wider variety of molecular alterations caused
by hSgo1 downregulation.
At first, the low proliferation rate in hSgo1 knockdown cells
seemed to suggest that hSgo1 authentically suppresses tumour
progression, but the subsequent FACS analysis and time-lapse
imaging analysis revealed that hSgo1 knockdown cells were
blocked in the mitotic phase, which is consistent with the
observation and previous reports.8 9 Moreover, there was a larger
cell population with a .4N DNA content, implying that hSgo1
knockdown leads to a partial mitotic block and escape into the
next cycle as aneuploid or polyploid cells or proceed to mitotic
catastrophe. The high frequency of aneuploidy/polyploidy
observed in the FISH analysis of hSgo1 knockdown cells
validated this conclusion. Several previous reports have
described a similar phenomenon as the effect of alterations.
Sotillo et al reported that cells arrest in G2/M when MAD2 is
overexpressed and escape from mitotic block,25 and Hernando et
al recently reported that MAD2 overexpression in IMR90
primary fibroblasts did not lead to a permanent block but to
escape into the next cycle and generation of cells with .4N
content.37 In these lines, we expected that hSgo1 dysfunction
may induce CIN through G2/M arrest. Actually, the FISH
analysis showed a higher percentage of tetraploid cells than that
of other aneuploid/polyploid cells in the hSgo1 shRNA group.
Tetraploid cells can arise through mitotic slippage or cytokinesis
failure, which result in binucleated cells.31 Moreover, super-
numerical centrosomes are a consequence of tetraploid forma-
tion,38 as we observed in hSgo1 knockdown cells. By observing
tetraploid cells, centrosome amplification and binucleated cells,
we succeeded in observing the process of diploid colon cancer
cells developing CIN as a result of knockdown of hSgo1 in real
time. In view of the above circumstances, ‘‘cell growth
suppression’’ by hSgo1 downregulation at first glance may not
simply be the same as ‘‘tumour suppression’’, but it is an
important step on the path to aneuploidy.
In conclusion, the results of this study showed that the
hSgo1-downregulated colorectal cancer has a clinicopathological
character of CIN and that hSgo1 downregulation leads to CIN
in human colorectal cancer cells. These results may be of help in
determining the molecular mechanism of the CIN pathway in
colorectal cancer progression.
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